Hodgkin lymphoma: Current status and clinical trial recommendations

Catherine S. Diefenbach, Joseph M. Connors, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl, Richard F. Little, Lawrence Baizer, Andrew Evens, Richard T. Hoppe, Kara M. Kelly, Daniel O. Persky, Anas Younes, Lale Kostakaglu, Nancy L. Bartlett

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN.

Original languageEnglish (US)
Article numberdjw249
JournalJournal of the National Cancer Institute
Volume109
Issue number4
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hodgkin Disease
Clinical Trials
Standard of Care
Neoplasms
Biomarkers

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Diefenbach, C. S., Connors, J. M., Friedberg, J. W., Leonard, J. P., Kahl, B. S., Little, R. F., ... Bartlett, N. L. (2017). Hodgkin lymphoma: Current status and clinical trial recommendations. Journal of the National Cancer Institute, 109(4), [djw249]. https://doi.org/10.1093/jnci/djw249
Diefenbach, Catherine S. ; Connors, Joseph M. ; Friedberg, Jonathan W. ; Leonard, John P. ; Kahl, Brad S. ; Little, Richard F. ; Baizer, Lawrence ; Evens, Andrew ; Hoppe, Richard T. ; Kelly, Kara M. ; Persky, Daniel O. ; Younes, Anas ; Kostakaglu, Lale ; Bartlett, Nancy L. / Hodgkin lymphoma : Current status and clinical trial recommendations. In: Journal of the National Cancer Institute. 2017 ; Vol. 109, No. 4.
@article{dcaabf0b6a2e4be8ac8bbe1a620c8cc3,
title = "Hodgkin lymphoma: Current status and clinical trial recommendations",
abstract = "The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN.",
author = "Diefenbach, {Catherine S.} and Connors, {Joseph M.} and Friedberg, {Jonathan W.} and Leonard, {John P.} and Kahl, {Brad S.} and Little, {Richard F.} and Lawrence Baizer and Andrew Evens and Hoppe, {Richard T.} and Kelly, {Kara M.} and Persky, {Daniel O.} and Anas Younes and Lale Kostakaglu and Bartlett, {Nancy L.}",
year = "2017",
month = "1",
day = "1",
doi = "https://doi.org/10.1093/jnci/djw249",
language = "English (US)",
volume = "109",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

Diefenbach, CS, Connors, JM, Friedberg, JW, Leonard, JP, Kahl, BS, Little, RF, Baizer, L, Evens, A, Hoppe, RT, Kelly, KM, Persky, DO, Younes, A, Kostakaglu, L & Bartlett, NL 2017, 'Hodgkin lymphoma: Current status and clinical trial recommendations', Journal of the National Cancer Institute, vol. 109, no. 4, djw249. https://doi.org/10.1093/jnci/djw249

Hodgkin lymphoma : Current status and clinical trial recommendations. / Diefenbach, Catherine S.; Connors, Joseph M.; Friedberg, Jonathan W.; Leonard, John P.; Kahl, Brad S.; Little, Richard F.; Baizer, Lawrence; Evens, Andrew; Hoppe, Richard T.; Kelly, Kara M.; Persky, Daniel O.; Younes, Anas; Kostakaglu, Lale; Bartlett, Nancy L.

In: Journal of the National Cancer Institute, Vol. 109, No. 4, djw249, 01.01.2017.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Hodgkin lymphoma

T2 - Current status and clinical trial recommendations

AU - Diefenbach, Catherine S.

AU - Connors, Joseph M.

AU - Friedberg, Jonathan W.

AU - Leonard, John P.

AU - Kahl, Brad S.

AU - Little, Richard F.

AU - Baizer, Lawrence

AU - Evens, Andrew

AU - Hoppe, Richard T.

AU - Kelly, Kara M.

AU - Persky, Daniel O.

AU - Younes, Anas

AU - Kostakaglu, Lale

AU - Bartlett, Nancy L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN.

AB - The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials. Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN.

UR - http://www.scopus.com/inward/record.url?scp=85016056099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016056099&partnerID=8YFLogxK

U2 - https://doi.org/10.1093/jnci/djw249

DO - https://doi.org/10.1093/jnci/djw249

M3 - Review article

C2 - 28040700

VL - 109

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

M1 - djw249

ER -

Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF et al. Hodgkin lymphoma: Current status and clinical trial recommendations. Journal of the National Cancer Institute. 2017 Jan 1;109(4). djw249. https://doi.org/10.1093/jnci/djw249